SCHEDULE 13G/A: Wasatch Advisors LP Discloses 10.5% Stake in C4 Therapeutics

Wasatch Advisors LP has filed an amended Schedule 13G, revealing a 10.5% beneficial ownership stake in C4 Therapeutics, Inc., as of April 30, 2025.

Summary

• Wasatch Advisors LP, an investment adviser, reported beneficial ownership of 7,473,332 shares of C4 Therapeutics, Inc. common stock.
• This represents 10.5% of the company's outstanding common stock.
• Wasatch Advisors LP holds sole voting power over 6,754,534 shares and sole dispositive power over all 7,473,332 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of C4 Therapeutics, Inc.

Sentiment

Score: 7

Explanation: The filing of a Schedule 13G by Wasatch Advisors LP, disclosing a 10.5% beneficial ownership in C4 Therapeutics, Inc., is a positive signal of institutional confidence in the company's prospects. While it doesn't reflect operational performance, it suggests a favorable view from a significant investor.

Positives

• A significant 10.5% stake by an institutional investment adviser like Wasatch Advisors LP can signal confidence in C4 Therapeutics, Inc.'s long-term prospects.
• The acquisition of shares in the ordinary course of business suggests a strategic investment rather than an activist play.

Industry Context

This filing indicates continued institutional interest in the biotechnology sector, specifically in companies like C4 Therapeutics, Inc. that are likely involved in drug discovery and development. Significant stakes by investment advisers often reflect a belief in the company's pipeline, market potential, or strategic direction within the competitive biotech landscape.

Comparison to Industry Standards

• A 10.5% beneficial ownership stake by an investment adviser is a substantial position, indicating a high level of conviction in C4 Therapeutics, Inc.
• While specific comparable companies or projects are not mentioned in this filing, such a significant stake by a reputable firm like Wasatch Advisors LP is generally viewed positively within the investment community, suggesting that the company's valuation or future prospects are considered attractive relative to peers in the biotech industry.

Stakeholder Impact

• Shareholders may view this as a positive indicator, potentially increasing investor confidence and attracting further institutional interest.
• The company's management might see this as validation of their strategy and a stable long-term investor.

Key Dates

Recommendation

Keywords

C4 Therapeutics, Wasatch Advisors LP, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biotechnology, SEC Filing, CT4, Investment Adviser